symptoms of endometrial hyperplasia or cancer. 3 “If we, as major bodies that put forth guidelines, aren't always in concert, imagine what our patients encounter when they call their gynecologist's office to schedule these appointments,” she said. Yet
Search Results
Improving Care Coordination to Optimize Health Outcomes in Cancer Survivors
Linda Overholser and Carlin Callaway
The Sonographic Findings and Differing Clinical Implications of Simple, Complicated, and Complex Breast Cysts
John G. Huff
spectrum of sonographic features that may range from predominately solid lesions reflecting hyperplasia and fibrosis, to clusters of microcysts, to macrocysts with internal echoes that may be difficult to distinguish from solid masses. 2 This article
Current Approaches in Hereditary Nonpolyposis Colorectal Cancer
Patrick M. Lynch
performed and yielded 3 atypical hyperplasias and 1 endometrial carcinoma. This yield compared favorably with the 1 atypical hyperplasia and 2 endometrial carcinomas detected in 28 patients sampled for abnormal surveillance results (pelvic exam, transvaginal
Uterine Neoplasms, Version 1.2014
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian, and Miranda Hughes
wish to preserve their fertility. 95 - 98 Likewise, it may also be selectively used for young patients with endometrial hyperplasia who desire fertility preservation. For the 2014 update, the panel added a new algorithm for fertility-sparing therapy in
Breast Cancer Risk Reduction, Version 2.2015
Therese B. Bevers, John H. Ward, Banu K. Arun, Graham A. Colditz, Kenneth H. Cowan, Mary B. Daly, Judy E. Garber, Mary L. Gemignani, William J. Gradishar, Judith A. Jordan, Larissa A. Korde, Nicole Kounalakis, Helen Krontiras, Shicha Kumar, Allison Kurian, Christine Laronga, Rachel M. Layman, Loretta S. Loftus, Martin C. Mahoney, Sofia D. Merajver, Ingrid M. Meszoely, Joanne Mortimer, Lisa Newman, Elizabeth Pritchard, Sandhya Pruthi, Victoria Seewaldt, Michelle C. Specht, Kala Visvanathan, Anne Wallace, Mary Ann Bergman, and Rashmi Kumar
, reproductive history, and lifestyle; and other factors, such as number of breast biopsies, especially those with a finding of flat epithelial atypia, atypical hyperplasia (AH), or lobular carcinoma in situ (LCIS); breast density: or prior thoracic irradiation
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Manisha H. Shah, Whitney S. Goldner, Al B. Benson III, Emily Bergsland, Lawrence S. Blaszkowsky, Pamela Brock, Jennifer Chan, Satya Das, Paxton V. Dickson, Paul Fanta, Thomas Giordano, Thorvardur R. Halfdanarson, Daniel Halperin, Jin He, Anthony Heaney, Martin J. Heslin, Fouad Kandeel, Arash Kardan, Sajid A. Khan, Boris W. Kuvshinoff II, Christopher Lieu, Kimberly Miller, Venu G. Pillarisetty, Diane Reidy, Sarimar Agosto Salgado, Shagufta Shaheen, Heloisa P. Soares, Michael C. Soulen, Jonathan R. Strosberg, Craig R. Sussman, Nikolaos A. Trikalinos, Nataliya A. Uboha, Namrata Vijayvergia, Terence Wong, Beth Lynn, and Cindy Hochstetler
hyperparathyroidism before age 30, multiple parathyroid adenomas, multigland hyperplasia (without obvious secondary causes), or recurrent primary hyperparathyroidism; (6) clinical suspicion for MEN2 due to the presence of medullary thyroid cancer or other combination
Breast Cancer: Noninvasive and Special Situations
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff
are limited to the lobular and ductal epithelium. In both the lobular and ductal epithelium, a spectrum of proliferative abnormalities may be seen, including hyperplasia, atypical hyperplasia, in situ carcinoma, and invasive carcinoma. 4 Approximately
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018
Manisha H. Shah, Whitney S. Goldner, Thorvardur R. Halfdanarson, Emily Bergsland, Jordan D. Berlin, Daniel Halperin, Jennifer Chan, Matthew H. Kulke, Al B. Benson III, Lawrence S. Blaszkowsky, Jennifer Eads, Paul F. Engstrom, Paul Fanta, Thomas Giordano, Jin He, Martin J. Heslin, Gregory P. Kalemkerian, Fouad Kandeel, Sajid A. Khan, Wajih Zaheer Kidwai, Pamela L. Kunz, Boris W. Kuvshinoff II, Christopher Lieu, Venu G. Pillarisetty, Leonard Saltz, Julie Ann Sosa, Jonathan R. Strosberg, Craig A. Sussman, Nikolaos A. Trikalinos, Nataliya A. Uboha, Jonathan Whisenant, Terence Wong, James C. Yao, Jennifer L. Burns, Ndiya Ogba, and Griselda Zuccarino-Catania
neuroendocrine cell hyperplasia. In this case, a diagnosis of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia can be made. 25 This condition is generally indolent; however, if patients present with somatostatin receptor–positive disease and
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead
considered where appropriate (eg, the mass and/or microcalcifications are not clearly within the specimen). Management of DCIS After Primary Treatment DCIS falls between atypical ductal hyperplasia and invasive ductal carcinoma within the spectrum
Management of Primary Ovarian Insufficiency Symptoms in Survivors of Childhood and Adolescent Cancer
Emma Gargus, Rebecca Deans, Antoinette Anazodo, and Teresa K. Woodruff
decrease the risk of endometrial hyperplasia and cancer. Even so, women should be screened regularly for irregular, heavy bleeding, which can indicate endometrial hyperplasia and cancer. As an added bonus, combined estrogen/progesterone therapy not only
